tbuckley/cabot-search huggingface dataset:
Expression and Release of Interleukin-1 by Different Human Melanoma Cell Lines
Authors: A. Kock, A. Urbanski, T. A. Luger, T. Schwarz, Z. Peng, H. F. Kung, M. Micksche, M. Vetterlein, J. C. Ansel
Journal: JNCI Journal of the National Cancer Institute (1989)

The influence of immunologic parameterson the clinical course of malignant melanoma is increasingly evident. However, it is not known which factors contribute to the immunologic host reaction against malignant melanoma. Because epidermal cells and, in particular, normal as well as transformed keratinocytes recently have been demonstrated to release various immunomodulating cytokines, the capacity of melanoma cells to produce interleukin-1 (IL-1) was examined. Accordingly, supernatants derived from different melanoma cell lines contained significant levels of IL-1 activity. Upon high-performance liquid charomatogrphy (HPLC) gel filtration, elanoma cell-derived IL-1 (MEL-IL-1) exhibited molecular weight heterogeneity, and HPLC chro-matofocusing revealed major activity at pH 5.0 and minor activity at pH 7.0. A monoclonal antibody directed against monocyte-derived IL-1 blocked MEL-IL-1 activity significantly and was able to precipitate four species of biosynthetically radiolabeled MEL-IL-1 is (25, 17, 6, and 4 kilodaltons), suggesting that MEL-IL-1 is identical to monocyte-derived IL-1. This was also confirmed by Northern blot analysis detecting IL-1 α specific mRNA in melanoma cells by hybridization with a cDNA fragment encoding for IL-1α Thus, melanoma cells, like other epidermal cells, exhibit the capacity to release the immunomodulating cytokine IL-1 and, therefore, probably have the potency to influence host defense mechanisms directed against malignant melanoma.(J Natl Cancer Inst 1989; 81: 36−42]
Phase III AXIS Trial of Axitinib Versus Sorafenib in Patients with Metastatic Renal Cell Carcinoma: Asian Subgroup Analysis
Authors: H. Uemura, Y.-C. Ou, H.Y. Lim, Y. Tomita, T. Ueda, H. Menon, J. Chung, J. Guo, J. Tarazi, S. Kim, S. Naito, H. Akaza
Journal: Annals of Oncology (2012)
Abstract 1715: Estrogen receptor β induces apoptosis through PUMA independent of p53 in prostate cancer cells.
Authors: Prasenjit Dey, Jan-Ake Gustafsson, Anders M. Strom
Journal: Cancer Research (2013)

Abstract Estrogen receptor β1’s (ERβ1) expression is reduced during the progression of prostate cancer. In agreement with several studies indicating a tumor suppressive effect of ERβ, we find that expression of ERβ increases apoptosis in the prostate cancer cells. Cells expressing ERβ showed an increase in apoptotic cell population by TUNEL assay and flow cytometric analysis. In addition, cells expressing ERβ showed an increase in sub G1 cell population compared to the control cells. Also, ERβ decreases the expression of anti-apoptotic factor Bcl-2 and increases the expression of the pro-apoptotic factor PUMA. Regulation of PUMA was found to be independent of p53. Although phosphorylation of AKT was decreased by ERβ expression we could not see any reduction of phosphorylated FOXO3A, a known regulator of PUMA. On the other hand total mRNA and protein of FOXO3A increased indicating a direct regulation of FOXO3A by ERβ. Using non-transfected PC3 and LNCaP cells we could observe induction of FOXO3A and PUMA as well as apoptosis in response to added 3β-adiol, DPN or 8β-VE2 indicating that the small amount of ERβ expressed in these cell lines are sufficient to induce apoptosis in response to ERβ specific ligands. Overall, our study indicates an apoptotic action of ERβ and suggests that it can be advantageous to treat prostate cancer with ERβ agonist. Citation Format: Prasenjit Dey, Jan-Ake Gustafsson, Anders M. Strom. Estrogen receptor β induces apoptosis through PUMA independent of p53 in prostate cancer cells. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1715. doi:10.1158/1538-7445.AM2013-1715
Abstract 747: Development and evaluation of rational combination therapy with imidazoacridinones for human bladder cancer patients through the COXEN algorithm
Authors: Steven C. Smith, Dmytro Havaleshko, Kihyuck Moon, Alexander S. Baras, Stefan Bekiranov, Daniel J. Burke, Jae K. Lee, Dan Theodorescu
Journal: Cancer Research (2010)

Abstract In most patients, bladder cancer metastasis is incurable with current chemotherapy. To try to address this challenge, we have recently employed the novel COXEN algorithm (1) for in silico drug discovery. This approach utilized publicly available gene expression and in vitro sensitivity data for &amp;gt;40k compounds in NCI-60 cell line screen, from which concordant gene expression prediction models from COXEN enabled our discovery of an imidoazacridinone drug, NSC-637993, with high activity in vitro against forty bladder cancer cell lines (2). Examination of additional “hits” provided by COXEN revealed another compound in this class, C1311 (NSC-645809, Symadex) which is undergoing clinical trials in other tumor types. Our objective was to develop the foundation for use of C1311 in bladder cancer, alone and in rational combination with other clinically relevant agents. Herein, we demonstrate in a panel of 40 human bladder cancer cells that in vitro cytotoxicity profile for C1311 closely correlates that of NSC-637993 and compares favorably to that of standard of chemotherapeutics. Using genome-wide patterns of synthetic lethality of C1311 with ORF knockouts in budding yeast, we determined that combining C1311 with taxanes could provide mechanistically rational combinations for patients that have failed first line therapy with platinum based chemotherapy. To evaluate the biological relevance of these yeast findings in bladder cancer, we evaluated C1311 singly and in doublet combination with paclitaxel in the hollow fiber assay in mice, observing striking efficacy of the agents in vivo. Last, applying COXEN gene expression prediction from 40 bladder cancer cell lines to human patient tumors with known cisplatin-based chemotherapy response data (N=30) (3), we provide evidence that signatures of C1311 sensitivity exist even within patients exhibiting no change or progressive disease on standard of care agents. Taken together, these findings provide an exemplar for COXEN-based drug discovery and development, while demonstrating the utility of yeast genetics in guidance of rational combinations in vivo. Most importantly, the high activity of these agents in vitro and in vivo calls for clinical trials of these agents, while COXEN provides genomic biomarkers that may be used for patient selection. (1) Crunkhorn S. Nat Rev Drug Discov 2007;6:782-3. (2) Lee JK et al. PNAS 2007;104:13086-91. (3) Als et al. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4407-14. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 747.
SAT0351 Adipokines as New Laboratory Markers in Osteoarthritis
Authors: Y. R. Akhverdyan, B. V. Zavodovsky, L. E. Seewordova, Y. V. Polyakova, E. S. Simakova, I. A. Zborovskaya, V. E. Kononov
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> There is some data that osteoarthritis (OA) may be part of systemic lipid metabolism disorder. Some authors suppose that fat tissue may be origin of biologically active substances such as adiponectin, resistin, leptin and visfatin that may influence on chondrogenesis. Now there is a question about a level adipokines in degenerative diseases of joints. In this connection the researches related to studying of those markers in OA are relevant. <h3>Objectives</h3> The aim of the study was to improve diagnostic, to clarify OA pathogenesis by examining the levels of adiponectin, resistin, leptin and visfatin in OA sera. <h3>Methods</h3> We examined 80 patients with OA and 50 healthy donors (HD). Adipokines level were determined by indirect immunoenzyme method using a commercial test systems (Bio Vendor, cat № RD195023100 for adiponectin; Bio Vendor, cat № RD191016100 for resistin; DBC Inc cat № CAN-L-4260 for leptin and RaiBiotech, cat № EIA-VIS-1 for visfatin measuring). <h3>Results</h3> We revealed decrease of adiponectin levels in 28 (35%) OA patients (2 - in HD group (4%), chi-square=16,66, p&lt;0,001), increase of resistin levels – in 31 (38,75%) (1 - in HD (2%), chi-square=22,39, p&lt;0,001), leptin - in 26 (32,5%) (2 - in HD (4%), chi-square=14,79, p&lt;0,001), and visfatin - in 23 (28,75%) OA patients (3 - in HD (6%), chi-square=9,95, p&lt;0,001). These results indicate that lipid metabolism in OA may be disturbed. There was no significant difference in adipokines levels depending on the sex of OA patients. Resistin and leptin levels in patients with metabolic syndrome (mean BMI = 36,8 ± 3,3, corresponds to the degree of obesity II) were significantly higher than in those without metabolic syndrome. Low levels of adiponectin, high levels of resistin, leptin and visfatin were noted in patients with OA with reactive synovitis, radiographic stage III-IV, functional impairment of the joints III. We observed an inverse correlation between adiponectin level and CRP, ESR, and WOMAC index, Lequesne indeces for <i>gonarthrosis</i> and coxarthrosis, direct correlation between resistin, leptin, and visfatin levels and CRP, ESR and algofunctional indices. Follow weight reduction (5 kg in 3 months) resulted in significant decrease leptin and resistin levels, the severity of articular symptoms and manifestations of insulin resistance. <h3>Conclusions</h3> Thus adipokines may have important significance in pathogenesis of OA. We suppose adiponectin may be a protective factor in OA. Patients with increased levels of resistin, leptin and visfatin have more aggressive manifestations of OA. Osteoarthritis patients with low adiponectin level and a high level of resistin, leptin and visfatinhave more severe form of disease. <h3>Disclosure of Interest</h3> None Declared
Isolated Metastatic Adrenal Involvement with Colon Cancer and FDG Coincidence Detection Imaging
Authors: G Des Guetz, F Montravers,  Spatzierer, I Tabah, D Grahek, J N Talbot, J L Bouillot, E Pujade-Lauraine
Journal: Clinical Nuclear Medicine (2003)

DES GUETZ, G. M.D.*; MONTRAVERS, F. M.D.†; SPATZIERER, M.D.‡; TABAH, I. M.D.*; GRAHEK, D. M.D.†; TALBOT, J. N. M.D.†; BOUILLOT, J. L. M.D.§; PUJADE-LAURAINE, E. M.D.* Author Information
Overtube-assisted direct peroral pancreatoscopy using an ultraslim gastroscope in a patient suspected of having an intraductal papillary mucinous neoplasm
Authors: V. Prachayakul, P. Aswakul, U. Kachintorn
Journal: Endoscopy (2011)

A 68-year-old man who had presented with abdominal discomfort and undergone a computed tomography (CT) scan that had revealed cystic lesions in the pancreatic head was referred to us for endoscopic ultrasound (EUS). The endoscopic view showed a fish-mouth opening to the ampulla with mucin content ([Fig. 1]).
Long-Term Course of Patients with a Basal Diastolic Murmur and Predominant Mitral Stenosis
Authors: Melville G. Magida, David M. Roseman
Journal: New England Journal of Medicine (1961)

THIS study reviews the long-term clinical courses of patients with basal diastolic murmurs and dominant mitral stenosis.MethodsReviewed were the records of 81 patients under supervision in the same cardiac clinic since childhood, including 35 who died during the period of observation. Most of the patients were examined and followed by us. Selection was based entirely on the presence of a basal diastolic murmur, regardless of the site of its maximal intensity, in patients with mitral stenosis. Pulse pressure was considered increased when it exceeded 60 mm. and the diastolic blood pressure was 50 mm. or less.For purposes . . .
Delays and Difficulties in Assessing Metal-on-Metal Hip Implants
Authors: Joshua P. Rising, Ian S. Reynolds, Art Sedrakyan
Journal: New England Journal of Medicine (2012)

More than 500,000 U.S. patients have received metal-on-metal hip prostheses, most of which were implanted between 2003 and 2010. These prostheses entered the market through the 510(k) pathway at the Food and Drug Administration (FDA), whereby manufacturers need only demonstrate substantial equivalence to a device already on the market to gain approval. Unfortunately, there is now compelling evidence that these implants fail at a higher rate than hip prostheses made of other materials1; indeed, one type of metal-on-metal hip has a failure rate of nearly 50% at 6 years.2 Moreover, a number of unresolved questions related to these devices . . .
Double common bile duct visualized by SpyGlass cholangioscopy
Authors: K. Kawakubo, H. Isayama, N. Sasahira, H. Kogure, T. Sasaki, N. Yamamoto, Y. Nakai, K. Hirano, M. Tada, K. Koike
Journal: Endoscopy (2012)

A double common bile duct is an extremely rare anomaly of the biliary tract system, which was first described by Vesalius in 1543 [1]. Recent advances in radiologic examinations have facilitated the correct diagnosis and management of this condition, but visualization of the anomaly using cholangioscopy has not been reported [2]. We report the finding of a double common bile duct with ectopic drainage into the duodenal bulb, which was successfully visualized using the SpyGlass cholangioscope (Boston Scientific, Natick, Massachusetts, USA).
Predictors of outcomes of arthroscopic rotator cuff repair: A pilot study
Authors: J. Turnbull, T. Mackenzie, M. Walton, P. Monga, L. Funk
Journal: International Journal of Surgery (2015)

s / International Journal of Surgery 23 (2015) S15eS134 S88 Teaching Hospital, Dundee were recruited prospectively over a 2month period. Patients with dementia (AMT < 8), visual impairment were excluded. 59 patients recruited in loop-1 were given Likert scale questionnaires assessing knowledge of the hip fracture, treatments and complications. 64 patients recruited in loop-2 were given new information leaflets and completed the same questionnaire. Scores per question and total scores were assessed. Statistically significant improvement (p < 0.0001) was observed in understanding injury, treatment options, complications and prognosis. Total score improved from 11.7 to 18.5 (p < 0.0 001). Conclusion: We observed significant benefit to patients' understanding of hip fracture with new leaflet provision in addition to existing modalities. Further study to elucidate optimal information content and delivery is required. 0917: PREDICTORS OF OUTCOMES OF ARTHROSCOPIC ROTATOR CUFF REPAIR: A PILOT STUDY J. Turnbull , T. Mackenzie , M. Walton , P. Monga , L. Funk . University of Manchester Medical School, UK; Wrightington Hospital & University of
AB0251 Small intestine enteropathy in patients with rheumatoid arthritis and osteoarthritis.
Authors: P. Bradna, I. Tacheci, S. Rejchrt, T. Soukup, J. Toms, D. Bastecka, J. Bures
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Involvement of small intestine is demonstrable up to 72% of patients, using non-steroidal antirheumatic drugs (NSAIDs). Quite little is known about influence of principal diagnosis on incidence and severity of enteropathy. <h3>Objectives</h3> Aim of our study was to compare small bowel enteropathy in rheumatoid arthritis and osteoarthritis patients. <h3>Methods</h3> Capsule endoscopy is currently the leading method for non-invasive diagnostics of small bowel lesions. This method is safe, reproducible, with high diagnostic yield, discriminating extend localization, severity and character of lesions. We examined 37 rheumatoid arthritis (RA) patients and 14 patients, using NSAIDs on a regular basis for osteoarthritis (OA). Group of 13 healthy persons not using NSAIDs served as a control group. We excluded people with comorbidities potentially involving the bowel or leading to a blood loss. We evaluated extend, severity and localizations of lesions. Qualitative data were evaluated by Fisher's exact test, Armitage test or chi2 test, quantitative data were evaluated by Student's T-test or Mann Whitney test in case of nonparametric distribution <h3>Results</h3> We demonstrated enteropathy in 67.5% of rheumatoid arthritis patients, moderate or severe lesions in 20% of RA patients. In osteoarthritis group there was 42.9% patients with enteropathy, severe in 7% of them. In control group there was demonstrated only mild changes in 15% people. Moderate or severe lesions were not demonstrating in NSAIDs non-users. Lesions were equally frequent in ileum and jejunum, duodenum was involved rarely. The same distribution was demonstrated also in moderate and severe lesions. <h3>Conclusions</h3> Rheumatoid arthritis patients, using non-steroidal antirheumatic drugs have significantly more frequent and more severe lesions of small bowel then osteoarthritis NSAIDs users. Jejunum and ileum were involved with equal frequency and severity, duodenal involvement was rare. Next studies must reply, if differences are caused by genetic predisposition, co medication, or they are caused by direct impact of rheumatoid arthritis. <h3>Disclosure of Interest</h3> None Declared
Removable covered self-expanding metal stent for extraction of a large biliary stone in a patient on dual antiplatelet therapy
Authors: Enzo Masci, Alessandra Bizzotto, Monica Arena, Benedetto Mangiavillano
Journal: Endoscopy (2014)

A 76-year-old man, who had previously undergone coronary artery bypass grafting but had episodes of myocardial infarction despite dual antiplatelet therapy, was diagnosed with a large common bile duct (CBD) stone that was causing recurrent cholangitis. Based on general agreement among the cardiologists and hematologists, his antiplatelet agents were neither stopped nor replaced with bridging medication. He underwent endoscopic retrograde cholangiopancreatography (ERCP) without biliary sphincterotomy 7 days prior to referral to our unit. His cholangitis was temporarily treated with a straight plastic stent passing alongside the stone; however, within 3 days of the procedure, the stent had migrated distally.
Toward Increased Adoption of Complex Care Management
Authors: Clemens S. Hong, Melinda K. Abrams, Timothy G. Ferris
Journal: New England Journal of Medicine (2014)

Interview with Dr. Clemens Hong on promoting adoption of complex care management. (12:54)Download Increasing evidence supports using specially trained, primary care–integrated, complex care management teams to improve outcomes and reduce costs by addressing the needs of high-cost patients. Yet substantial barriers to more widespread adoption remain.
Pulmonary Targeting of Adeno-associated Viral Vectors by Next-generation Sequencing-guided Screening of Random Capsid Displayed Peptide Libraries
Authors: Jakob Körbelin, Timo Sieber, Stefan Michelfelder, Lars Lunding, Elmar Spies, Agnes Hunger, Malik Alawi, Kleopatra Rapti, Daniela Indenbirken, Oliver J Müller, Renata Pasqualini, Wadih Arap, Jürgen A Kleinschmidt, Martin Trepel
Journal: Molecular Therapy (2016)

Vectors mediating strong, durable, and tissue-specific transgene expression are mandatory for safe and effective gene therapy. In settings requiring systemic vector administration, the availability of suited vectors is extremely limited. Here, we present a strategy to select vectors with true specificity for a target tissue from random peptide libraries displayed on adeno-associated virus (AAV) by screening the library under circulation conditions in a murine model. Guiding the in vivo screening by next-generation sequencing, we were able to monitor the selection kinetics and to determine the right time point to discontinue the screening process. The establishment of different rating scores enabled us to identify the most specifically enriched AAV capsid candidates. As proof of concept, a capsid variant was selected that specifically and very efficiently delivers genes to the endothelium of the pulmonary vasculature after intravenous administration. This technical approach of selecting target-specific vectors in vivo is applicable to any given tissue of interest and therefore has broad implications in translational research and medicine. Vectors mediating strong, durable, and tissue-specific transgene expression are mandatory for safe and effective gene therapy. In settings requiring systemic vector administration, the availability of suited vectors is extremely limited. Here, we present a strategy to select vectors with true specificity for a target tissue from random peptide libraries displayed on adeno-associated virus (AAV) by screening the library under circulation conditions in a murine model. Guiding the in vivo screening by next-generation sequencing, we were able to monitor the selection kinetics and to determine the right time point to discontinue the screening process. The establishment of different rating scores enabled us to identify the most specifically enriched AAV capsid candidates. As proof of concept, a capsid variant was selected that specifically and very efficiently delivers genes to the endothelium of the pulmonary vasculature after intravenous administration. This technical approach of selecting target-specific vectors in vivo is applicable to any given tissue of interest and therefore has broad implications in translational research and medicine.
EARLY INVASIVE CORONARY STRATEGY IN COMATOSE SURVIVORS OF OUT OF HOSPITAL CARDIAC ARREST: RESULTS FROM A LARGE REGIONAL CARDIAC CENTRE
Authors: Sri Raveen Kandan, Hazim Rahbi, Kieron Rooney, Matthew Thomas, Philip Cowburn, Jonathan Benger, Andreas Baumbach, Thomas W. Johnson, Julian W. Strange
Journal: Journal of the American College of Cardiology (2016)
Cancer Charities Agree To Halt Sweepstakes Mailings--Refunds Offered
Authors: K. Ruddon
Journal: JNCI Journal of the National Cancer Institute (1989)

Cancer Charities Agree To Halt Sweepstakes Mailings—Refunds Offered Get access Kate Ruddon Kate Ruddon Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 81, Issue 17, 6 September 1989, Pages 1274–1276, https://doi.org/10.1093/jnci/81.17.1274 Published: 06 September 1989